Summit Therapeutics plc (SMMT) EPS Estimated At $-0.74

August 13, 2018 - By James Douglas

Summit Therapeutics plc (NASDAQ:SMMT) Logo

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.74 EPS on August, 30.They anticipate $1.84 EPS change or 167.27 % from last quarter’s $1.1 EPS. After having $-0.55 EPS previously, Summit Therapeutics plc’s analysts see 34.55 % EPS growth. The stock decreased 0.85% or $0.02 during the last trading session, reaching $2.33. About 51,620 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 11.61% since August 13, 2017 and is uptrending. It has underperformed by 0.96% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 7 analysts covering Summit Therapeutics (NASDAQ:SMMT), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Summit Therapeutics had 10 analyst reports since February 13, 2018 according to SRatingsIntel. SunTrust downgraded it to “Hold” rating and $4 target in Wednesday, June 27 report. The firm earned “Neutral” rating on Thursday, June 28 by Janney Capital. The stock has “Hold” rating by Oppenheimer on Wednesday, June 27. Canaccord Genuity maintained it with “Buy” rating and $28.0 target in Tuesday, March 6 report. SunTrust maintained the stock with “Buy” rating in Friday, April 13 report. The stock of Summit Therapeutics plc (NASDAQ:SMMT) earned “Buy” rating by Canaccord Genuity on Wednesday, April 11.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $39.70 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: which released: “Summit Therapeutics Joins Antimicrobials Working Group” on July 30, 2018. Also published the news titled: “Summit Therapeutics to Present at the Canaccord Genuity Growth Conference” on August 06, 2018.‘s news article titled: “Summit’s ridinilazole beats vancomycin in C. diff study” with publication date: August 02, 2018 was also an interesting one.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.